Download Evaluating the role of has-miR-21-3p in Cisplatin resistance ovarian

Evaluating the role of has-miR-21-3p in Cisplatin resistance ovarian cancer cells.
Authors: Joel Encarnación-Rosado1, Pablo E. Vivas-Mejía 2
University of Puerto Rico – Río Piedras Campus1, San Juan, PR
Department of Biochemistry & Cancer Center, Medical Sciences Campus, University of
Puerto Rico2
Ovarian cancer has the highest mortality rate among all gynecologic malignancies. The
poor treatment of this disease is relate with it drug resistance. Understand the main
mechanism in which the ovarian cancer cells become resistant to chemotherapy is one
of the major challenges of this malignance. The overall goal of this project is to design
microRNA-based therapies for advanced stages in epithelial ovarian cancers.
MicroRNAs (miRNAs) are small non-coding RNAs (~21-23 nucleotides) involve in gene
regulation by sequence specific binding to the 3’-untranslated regions (3’-UTR) of
messenger RNAs (mRNAs). Several independent reports have demonstrated that
different miRNAs are involved in tumor initiation, progression and drug resistance.
Previous data from our lab shown miR-21-5p inhibit the translation of important proteins
related with cisplatin resistance. In this project will be evaluate the role during drug
resistance of the primary transcript of miR-21, best known as miR-21-3p. The first aim
of this project is to identify the targets relate with mir-21-3p during Cisplatin resistance.
Then we are going to validate the importance of these targets and evaluate its effects in
different cell lines. And last, we are going to perform different in vivo assays to confirm
our findings.